Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-5.92% $0.506
America/New_York / 17 apr 2024 @ 14:28
FUNDAMENTALS | |
---|---|
MarketCap: | 13.28 mill |
EPS: | -2.69 |
P/E: | -0.190 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 26.26 mill |
Avg Daily Volume: | 1.681 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.190 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.190 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.485 (-4.10%) $-0.0207 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 0.454 - 0.558 ( +/- 10.28%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-29 | Tosca Melissa | Buy | 60 000 | Stock Option (right to buy) |
2023-09-29 | Tosca Melissa | Buy | 30 000 | Common Stock |
2023-09-29 | Daniels Eric Joseph | Buy | 125 000 | Stock Option (right to buy) |
2023-09-29 | Daniels Eric Joseph | Buy | 62 500 | Common Stock |
2023-09-29 | Strem Brian M. | Buy | 150 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 1 933 640 | Sell: 3 426 001 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.506 (-5.92% ) |
Volume | 0.145 mill |
Avg. Vol. | 1.681 mill |
% of Avg. Vol | 8.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:30 | sell | $0.680 | N/A | Active |
---|
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.